Regenerex Pharma, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
Regenerex Pharma reported a significantly increased net loss and substantial cash burn for the six months ended September 30, 2025, with zero revenue, raising substantial doubt about its ability to continue as a going concern.
Regenerex Pharma, Inc. reported a significantly increased net loss of $663,584 for Q2 2025, with zero revenue and substantial doubt about its ability to continue as a going concern.
Regenerex Pharma's Q3 2024 filing reveals a decreased net loss compared to the previous year, as the company continues to develop and market wound care products.
Regenerex Pharma's Q2 2024 results show a decreased net loss compared to the same period last year, as the company continues to develop and market wound care products.
Regenerex Pharma's Q1 2024 filing reveals a widening net loss and continued reliance on debt financing as the company prepares to launch its wound care products.
10-Q: Regenerex Pharma Reports Increased Net Loss in Q3 2023 Amidst Intellectual Property Investments
Regenerex Pharma's Q3 2023 report reveals a significant increase in net loss due to intellectual property acquisition and increased operating expenses.